A detailed history of Boston Trust Walden Corp transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Boston Trust Walden Corp holds 960 shares of VRTX stock, worth $432,355. This represents 0.0% of its overall portfolio holdings.

Number of Shares
960
Previous 1,110 13.51%
Holding current value
$432,355
Previous $520,000 14.23%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$460.0 - $505.78 $69,000 - $75,867
-150 Reduced 13.51%
960 $446,000
Q2 2022

Jul 22, 2022

SELL
$234.96 - $292.55 $21,146 - $26,329
-90 Reduced 7.5%
1,110 $313,000
Q4 2021

Jan 21, 2022

SELL
$177.01 - $223.45 $5,841 - $7,373
-33 Reduced 2.68%
1,200 $264,000
Q3 2021

Oct 25, 2021

BUY
$181.39 - $202.99 $5,985 - $6,698
33 Added 2.75%
1,233 $224,000
Q4 2020

Jan 15, 2021

SELL
$207.01 - $276.09 $63,759 - $85,035
-308 Reduced 20.42%
1,200 $284,000
Q3 2018

Oct 23, 2018

SELL
$167.73 - $192.74 $8,386 - $9,637
-50 Reduced 3.21%
1,508 $291,000
Q1 2018

Apr 13, 2018

SELL
$151.6 - $177.13 $94,750 - $110,706
-625 Reduced 28.63%
1,558 $254,000
Q3 2017

Oct 13, 2017

BUY
$148.13 - $162.24 $323,367 - $354,169
2,183
2,183 $332,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Boston Trust Walden Corp Portfolio

Follow Boston Trust Walden Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boston Trust Walden Corp, based on Form 13F filings with the SEC.

News

Stay updated on Boston Trust Walden Corp with notifications on news.